CertaPeptides SEMAX and SELANK Promo-Code, Product, and COA Detailed FAQ: LOOT30 for Up to 30% Off

SEMAX and SELANK occupy a distinctive corner of the current CertaPeptides neuropeptide catalog. Both are short synthetic peptides with published experimental literature, but they are not interchangeable, their research histories are not equally strong across every claimed endpoint, and the analytical documentation attached to a vial matters just as much as the product name.

Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.

Research-use notice: CertaPeptides products discussed here are supplied for controlled in-vitro/laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation.

Qualified laboratory buyers reviewing CertaPeptides can access the CertaPeptides LOOT30 research catalog and use promo code LOOT30 for up to 30% off. The commercial offer should be considered only after the compound, batch documentation, research suitability, and analytical evidence have been evaluated.

This FAQ focuses specifically on SEMAX, SELANK, the SEMAX + SELANK blend, and the related CertaPeptides neuropeptide research cluster that includes Adamax, PE 22-28, Cerebrolysin, VIP, DSIP, and Dermorphin. The objective is to separate molecular identity, published evidence, vendor documentation, and COA interpretation so researchers can compare these materials without treating an entire “neuropeptide” category as though every product has the same mechanism or evidence base.

What is SEMAX?

SEMAX is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design is based on an ACTH-derived fragment joined to a Pro-Gly-Pro sequence. Experimental interest in SEMAX has centered largely on neurotrophic signaling, gene-expression changes, inflammatory pathways, and models of cerebral ischemia.

The important qualification is that a large portion of the mechanistic literature consists of cell-culture and animal studies. For example, rat studies have reported changes in BDNF and NGF gene expression after SEMAX exposure, while other preclinical work has investigated BDNF protein levels, neurotrophin-receptor transcription, and inflammatory gene-expression patterns.

These studies are useful for identifying research hypotheses. They do not justify converting SEMAX into a general claim about cognition, neurological treatment, mood, memory enhancement, or other personal outcomes.

The current CertaPeptides SEMAX listing describes a supplier batch specification of at least 98% and identifies selected independently tested lots. Its current public documentation includes a Janoshik-tested 10 mg SEMAX record reported at 99.477% purity with measured content of 10.93 mg, or 109.3% of label, for that specific tested lot.

That wording matters. A result from one independently tested lot should not automatically be applied to every SEMAX vial, size, or future batch.

What is SELANK?

SELANK is also a synthetic heptapeptide, but it has a different molecular origin from SEMAX. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, and it is commonly described as a stabilized analog based on the endogenous immunomodulatory peptide tuftsin.

Published research has examined SELANK in relation to GABA-associated signaling, neuropeptide regulation, and experimental anxiety-related models. A molecular review indexed by PubMed describes work in which SELANK affected radioligand GABA binding and was investigated as a possible positive allosteric modulator in experimental systems.

Again, this is a research finding rather than a recommendation for human use.

The CertaPeptides product page currently lists SELANK as a lyophilized research material and describes a supplier batch specification of at least 98%, with selected lots independently tested. Its public COA archive includes a SELANK report showing 99.788% purity for a tested lot dated March 31, 2026.

SEMAX and SELANK may therefore appear next to one another in a supplier catalog, but their sequences, proposed mechanisms, experimental traditions, and source literature are different.

What is the simplest difference between SEMAX and SELANK?

The most useful distinction is molecular rather than promotional.

SEMAX is an ACTH-fragment-derived synthetic peptide whose published experimental literature includes neurotrophin signaling, BDNF/NGF expression, transcriptomic changes, inflammatory pathways, and ischemia models. SELANK is a tuftsin-derived peptide whose literature includes GABA-related signaling, neuropeptide regulation, and immunomodulatory research.

A shared commercial category does not make them substitutes for each other.

Researchers designing assays should therefore start with the experimental question. If a study is investigating BDNF-related transcription, for example, the SEMAX literature provides one kind of precedent. If the study is examining tuftsin-derived peptide activity or GABA-associated molecular signaling, SELANK presents a different background.

The distinction should remain clear even when both compounds are sold together as a blend.

Does CertaPeptides sell SEMAX and SELANK individually?

Yes. Current CertaPeptides pages list SEMAX and SELANK separately, while the catalog also includes a SEMAX + SELANK blend.

This is useful from a research-design perspective because an investigator may want one defined compound rather than a mixed material.

For single-compound work, the individual vial generally produces a conceptually cleaner starting point because the independent variable is easier to define. A two-component formulation may instead be relevant where the experiment itself is intentionally designed around exposure to both components.

Neither format is inherently “better.” They answer different experimental questions.

What is the CertaPeptides SEMAX + SELANK Blend?

CertaPeptides currently lists a 20 mg co-formulated SEMAX + SELANK research blend.

According to the current product and analytical pages, a selected tested lot underwent content quantification through Janoshik Analytical. The published result reports 21.20 mg total material, consisting of 10.92 mg SELANK and 10.28 mg SEMAX, corresponding to 106% of the stated 20 mg total label amount for that tested lot.

This example illustrates why a blend should not always be judged using one generic “purity percentage.”

For a multi-component formulation, component-specific content can be more informative than collapsing the material into a single headline number. An investigator may need to know whether both expected components were measured and in what amounts.

CertaPeptides itself explains this distinction in its transparency material: blends that contain multiple active components may be analyzed through content quantification rather than represented by one single-compound purity percentage.

Is a SEMAX + SELANK blend the same as testing SEMAX and SELANK separately?

No.

A combined formulation introduces both materials into the same experimental condition. That changes the interpretation of any measured response.

With individual compounds, researchers can create separate SEMAX and SELANK conditions and evaluate each independently. A rigorous design could also include an appropriate combined condition if that comparison is relevant to the hypothesis.

The key point is experimental attribution: if two compounds are introduced simultaneously and an endpoint changes, the result alone may not reveal whether SEMAX, SELANK, their interaction, or another experimental factor drove the observation.

For that reason, the existence of a commercial blend should never be treated as evidence that combined exposure has been demonstrated to be superior.

What does the SEMAX research literature actually show?

The strongest responsible summary is that SEMAX has a meaningful experimental literature, but much of it is preclinical.

One PubMed-indexed rat study investigated the temporal dynamics of BDNF and NGF gene expression following SEMAX administration and found region- and time-dependent changes in the hippocampus and frontal cortex.

Another study reported specific binding in rat basal forebrain membranes and changes in BDNF protein levels in the experimental model.

Additional work has examined neurotrophin gene expression in rat brain, including BDNF and NGF-related changes.

Studies in ischemia models have examined transcriptional responses involving neurotrophins, inflammatory mediators, neurotransmitter-related genes, CREB, JNK, MMP-9 and other molecular markers.

That is a substantial experimental foundation for mechanism-oriented research, but evidence hierarchy remains important. Results from cultured cells and rodents cannot simply be translated into established human efficacy.

A careful article should therefore say that SEMAX has been studied in these pathways and models, rather than claiming that the CertaPeptides product produces a particular neurological outcome.

What does the SELANK research literature show?

SELANK's literature is different.

One PubMed-indexed molecular review summarizes experimental work involving GABA binding and discusses SELANK as a peptide-based anxiolytic research compound.

CertaPeptides' product documentation also identifies SELANK as a tuftsin-derived synthetic peptide and lists published research references connected to enzyme activity and neuropeptide biology.

The appropriate research takeaway is that SELANK has a molecular and preclinical literature relevant to neurobiology and peptide signaling.

It should not be marketed as though those experiments establish clinical effectiveness, recommended personal use, or a validated treatment pathway.

What is Adamax, and how strong is its evidence base?

Adamax appears in the wider neuropeptide-related commercial landscape, including within the CertaPeptides catalog.

Researchers should apply more caution here than they would with better-characterized compounds such as SEMAX.

Public descriptions of Adamax are not as standardized, and easily accessible peer-reviewed literature specifically centered on the commercially named compound is sparse. That makes it especially important not to use vendor descriptions as substitutes for an established scientific literature.

The practical rule is straightforward: separate evidence about a parent molecular family from evidence about the exact material being purchased.

If a supplier describes Adamax through analogy with another peptide, that analogy may generate a hypothesis, but it does not establish that the exact compound has identical pharmacology, stability, binding behavior, or experimental outcomes.

For procurement, researchers should examine the exact sequence or molecular identity, supplier specification, batch number, analytical method, and source documentation rather than relying on category labels such as “nootropic peptide” or “cognitive peptide.”

What is PE 22-28?

PE 22-28 has a clearer connection to published experimental research.

A PubMed-indexed study on shortened spadin analogs describes PE 22-28 as a seven-amino-acid peptide designed from degradation products of spadin. The researchers evaluated its interaction with TREK-1 potassium channels and reported higher affinity in an in-vitro hTREK-1/HEK system than the parent spadin peptide.

The same research program examined behavioral endpoints in animal models.

This gives PE 22-28 a different mechanistic research context from either SEMAX or SELANK. It should therefore not be discussed as simply another version of SEMAX/SELANK neuropeptide research.

Its most relevant experimental context is associated with TREK-1 channel biology and spadin-derived peptide research.

CertaPeptides currently includes PE 22-28 among its cyclic/neuropeptide research materials.

Can SEMAX, SELANK, Adamax and PE 22-28 be grouped together scientifically?

Only at a very broad catalog level.

Calling all four “neuropeptide research compounds” may be useful for navigation, but it says very little about mechanism.

SEMAX has an ACTH-fragment-related origin.

SELANK is tuftsin-derived.

PE 22-28 is associated with the spadin/TREK-1 research line.

Adamax requires particularly careful source checking because its accessible literature and commercial nomenclature are less standardized.

A researcher would therefore make a serious mistake by assuming that the four compounds target one receptor family or can be substituted for one another.

A better classification starts with sequence, molecular origin, proposed target or pathway, and the quality of direct experimental evidence.

Where does Cerebrolysin fit?

Cerebrolysin is analytically different again because it is not best understood as one single defined short synthetic peptide.

It is a peptide mixture.

That difference matters because a single-compound HPLC purity percentage is not necessarily an appropriate way to describe a complex peptide mixture.

Researchers reading CertaPeptides documentation should therefore distinguish between analytical records for a defined molecule and content or composition-oriented records for more complex materials.

The same principle applies generally: the analytical method should answer a meaningful question about the material being studied.

What about VIP, DSIP and Dermorphin?

These compounds broaden the neuropeptide category but do not make it more mechanistically uniform.

VIP, or vasoactive intestinal peptide, is an endogenous signaling peptide studied across neural, vascular, smooth-muscle and immune-related systems.

DSIP, commonly called delta sleep-inducing peptide, belongs to a historical area of neuropeptide investigation in which early experimental claims should be interpreted with attention to replication and evidence quality.

Dermorphin is different again because it is known primarily for strong opioid-receptor activity.

Putting these compounds in one online category may help shoppers browse a catalog, but a scientific study should never use the store category itself as a biological classification.

What is a Certificate of Analysis?

A Certificate of Analysis, or COA, is an analytical record associated with a particular material or batch.

For research peptides, a useful COA may include information such as product identity, batch or report code, test date, analytical laboratory, assay type, purity, measured content, chromatographic data, mass-spectrometry information, or other method-specific results.

The exact information depends on what was tested.

That final point is essential. A COA is not a magic certificate proving every conceivable quality attribute.

A chromatographic purity measurement answers a different question from molecular identity testing. Content quantification answers another question. Sterility, endotoxin, residual solvents, heavy metals and microbiological characteristics require their own appropriate tests.

Therefore, “has a COA” is not enough. The researcher should ask what the COA actually measures.

How does CertaPeptides organize its COA system?

CertaPeptides currently describes a two-level documentation model.

Its public COA vault contains independent third-party Janoshik reports for selected lots as well as supplier batch specifications covering other product lines. The company explicitly states that selected lots are independently tested on a rotating basis rather than claiming that every single vial receives independent third-party analysis.

That distinction is more informative than treating all certificates as equivalent.

A supplier batch specification is documentation from the supply chain.

An independent third-party analytical report provides an additional layer of external measurement for the particular sample or lot that was tested.

Researchers should identify which of those applies to their actual batch.

How should a researcher verify a CertaPeptides batch?

Start with the identifier printed on the vial or associated documentation.

CertaPeptides currently provides a public verification interface that accepts a vial batch number or laboratory report code. Its stated purpose is to connect that identifier with either a supplier batch specification or an independent third-party record.

The strongest workflow is therefore:

1. Record the exact product name and vial batch number.

2. Search that batch in the supplier's verification system.

3. Determine whether the displayed record is an independent laboratory report or a supplier specification.

4. Check the compound name and tested amount.

5. Check the test date.

6. Check which analytical method or measurements were actually performed.

7. Where an independent laboratory link is available, compare the supplier's record with the laboratory's own record.

8. Save the documentation used for the experiment with the laboratory's procurement and study records.

This creates a traceable evidence trail between the physical vial and the analytical record.

What does the current CertaPeptides COA page show for SEMAX?

The current public archive includes an independently verified SEMAX entry reporting 99.477% purity and 10.93 mg measured content for a 10 mg tested lot. The listed test date is August 6, 2026.

This can be useful evidence about that particular tested material.

It should not be converted into a timeless statement that every SEMAX vial CertaPeptides has ever sold is 99.477% pure.

Batch-specific evidence should remain batch-specific.

What does the current COA page show for SELANK?

The public COA archive also lists an independently verified SELANK entry at 99.788% purity with a test date of March 31, 2026.

Again, that number belongs to the tested report.

A researcher purchasing a different lot should match the lot identifier rather than simply citing the best historical result available on the website.

What does the COA show for the SEMAX + SELANK blend?

For the 20 mg blend, the relevant public analytical record is content-based.

CertaPeptides reports 21.20 mg total, separated as 10.92 mg SELANK and 10.28 mg SEMAX for the tested sample.

This is a good illustration of method-to-question matching.

For a two-component formulation, determining how much of each named component was detected can be more meaningful than trying to create one misleading purity percentage for the entire mixed material.

Does “99% purity” mean a peptide vial contains exactly the labeled amount?

No.

Purity and content are different concepts.

A sample can contain a highly pure target compound while the total amount of that material in a vial differs from the nominal label claim. Conversely, a vial may contain approximately the expected mass while impurities still affect its chromatographic purity.

That is why CertaPeptides' current transparency material separates purity from measured-content results when both are available.

When researchers compare COAs, the first question should therefore be: “What exactly does this number represent?”

Does HPLC prove molecular identity?

Not by itself.

High-performance liquid chromatography is extremely useful for separating components and assessing chromatographic purity under a defined method. It does not automatically prove every aspect of molecular identity.

Mass spectrometry, sequence analysis, or other analytical approaches may be needed depending on the research question.

Similarly, a mass measurement that is consistent with an expected molecule does not automatically establish sterility, endotoxin status, solvent profile, or every other quality characteristic.

A high-quality procurement review should avoid compressing multiple analytical concepts into the single word “tested.”

Is a Janoshik report the same thing as regulatory approval?

No.

An independent analytical report is evidence about the sample and measurements reported by the laboratory.

It is not regulatory authorization for clinical use.

CertaPeptides' own current policy states that its materials are supplied for laboratory research and are not for human or veterinary use.

Analytical verification and regulatory status are separate questions.

Is every CertaPeptides product independently tested?

CertaPeptides does not currently claim independent third-party testing for every individual batch.

Its transparency page explicitly says independent testing is performed on selected lots on a rolling cycle and that supplier specifications cover product lines in between.

This makes batch matching particularly important.

Researchers should avoid converting the existence of multiple Janoshik reports into the broader claim that every vial or every production lot has been individually tested by Janoshik.

What documentation should a laboratory save?

For reproducibility, procurement documentation should ideally preserve more than an order confirmation.

The laboratory should retain the product name, supplier, batch number, date received, COA or supplier specification used, analytical-laboratory report identifier where applicable, storage records, and any internal sample identifier assigned by the laboratory.

If the experiment later needs to be repeated, the team should be able to determine whether the second material came from the same batch or a different one.

This is particularly important for research peptides because literature reproducibility can be affected by compound identity, purity, content, degradation, storage conditions, and differences between batches.

Should researchers choose between SEMAX and SELANK based on the higher purity number?

Not necessarily.

A higher historical purity number does not tell researchers which molecule fits their scientific hypothesis.

Choosing a compound begins with mechanism and study design, not a decimal-point contest between unrelated peptides.

If a SEMAX experiment requires a specific ACTH-fragment-derived research material, a historical SELANK purity result is irrelevant to that question.

Similarly, the existence of a high-purity SEMAX COA does not make SEMAX an appropriate substitute in a study explicitly designed around a tuftsin-derived sequence.

Documentation supports compound selection; it does not replace biological reasoning.

What does “research use only” mean here?

For CertaPeptides, the company's current FAQ and affiliate materials state that products are intended for in-vitro laboratory research and are not intended for human consumption, veterinary use, or clinical application.

That boundary also shapes responsible affiliate content.

Research articles can discuss molecular identity, published laboratory findings, assay concepts, experimental models, analytical testing, batch verification, supplier documentation and logistics.

They should not turn those discussions into dosing schedules, injection directions, treatment protocols, personal stacks, medical advice, weight-loss instructions, performance-enhancement guidance, or recommendations for self-experimentation.

Where does CertaPeptides currently ship?

The current CertaPeptides shipping page states that it serves all 27 European Union member states plus Switzerland, the United Kingdom, Iceland, and Serbia.

That produces 31 listed destinations under the current policy.

The same page identifies different carriers depending on route, including Sameday, GLS, TCE Worldwide and DHL Express. Delivery estimates and prices differ by destination.

Because logistics policies can change much faster than peptide literature, researchers should use the current official shipping page rather than relying on an older article.

Shipping availability itself also does not establish whether a particular import, possession, or research activity is lawful for every recipient. Laboratories remain responsible for destination-country requirements.

What is CertaPeptides' current return framework?

The company's current returns policy states that unopened qualifying products can generally be returned within 14 days of delivery, subject to its conditions.

It also provides a process involving support contact, an RMA, return of eligible sealed products, and reimbursement according to the policy. Damaged shipments have a separate reporting process.

Researchers should consult the current official page before ordering because a secondary article may preserve an older version of the policy.

What role should the LOOT30 discount play in a research purchase?

A secondary one.

The responsible order is:

Define the research question.

Identify the required compound.

Review the relevant literature.

Confirm the product identity and form.

Check the actual batch documentation.

Determine whether the record is supplier-issued or independently measured.

Review shipping and procurement requirements.

Then consider price.

For qualified researchers who decide that CertaPeptides fits those requirements, LOOT30 provides up to 30% off through the campaign affiliate destination.

The discount does not increase purity, strengthen a weak study, transform preclinical findings into clinical evidence, or make an unsuitable compound appropriate for an experiment.

Can LOOT30 be used for SEMAX and SELANK?

LOOT30 is the campaign promo code associated with this CertaPeptides affiliate offer and is presented as up to 30% off.

Researchers interested in SEMAX, SELANK, or the broader catalog can begin through the CertaPeptides LOOT30 research shop.

The phrase “up to 30% off” is important: it should not be rewritten as “30% off every order,” “flat 30% off,” or another broader claim.

Is LOOT30 evidence that CertaPeptides is a better supplier?

No.

A promotional code is commercial information.

Supplier evaluation should instead look at whether the company clearly identifies its legal entity, whether batch numbers can be matched to documentation, whether independent reports are accessible where claimed, whether analytical scope is explained accurately, and whether research-use restrictions and shipping policies are stated clearly.

CertaPeptides currently identifies its operating legal entity as CERTALAB S.R.L. in Romania and describes itself as a reseller rather than the original manufacturer of every compound.

Those facts are far more relevant to due diligence than a coupon percentage.

What are common COA red flags?

A few issues deserve attention regardless of supplier.

A certificate should not be treated as strong evidence if it cannot be connected to the physical batch being purchased.

A purity percentage without a named analytical method provides limited context.

A certificate that confuses purity, identity and content may create more questions than it answers.

A blend represented by one unexplained purity percentage may require further examination because multi-component materials can call for component-specific analysis.

A supplier that implies every batch is independently tested when only selected historical samples have been tested is overstating the evidence.

And a laboratory report should be examined for the exact test date, sample description, report identifier and issuing laboratory rather than judged from a screenshot of a headline number.

CertaPeptides' own transparency report makes a related point: purity is not identical to identity and neither is identical to unrelated quality measurements such as heavy-metal analysis.

Should a researcher trust a product just because a COA is published?

No single document should replace scientific judgment.

A COA can materially improve transparency, especially when it is independently verifiable and matched to a batch.

But supplier evaluation can also include legal identity, storage and shipping practices, documentation consistency, return policy, responsiveness to discrepancies, and whether public statements stay within the actual scope of testing.

The most useful mindset is not “Does this supplier have a COA?”

It is “What does this specific record establish about this specific batch?”

Why does batch matching matter so much?

Peptide procurement is not an abstract comparison between brand names.

A laboratory receives physical material from a particular lot.

If the public report belongs to a different lot, it may still show that a supplier has previously commissioned independent testing, but it does not constitute direct evidence for the new vial.

CertaPeptides' public verification framework is therefore most valuable when the identifier on the actual vial maps directly to the analytical record a researcher reviews.

The closer the documentation is to the material actually used in the experiment, the stronger the traceability.

How should older CertaPeptides articles be used?

Older articles can provide useful background, but they should not override current official information for changeable facts such as catalog size, pricing, inventory, shipping countries, carriers, payment methods or returns.

For example, CertaPeptides' current official shipping page lists the current destination set and carrier framework.

Historical articles may reflect a different snapshot.

This distinction is especially important in a fast-changing 2026 catalog where new compounds and documentation records can appear over relatively short periods.

How strong is the scientific evidence for SEMAX compared with Adamax?

SEMAX currently has a clearer body of identifiable peer-reviewed experimental literature.

PubMed contains multiple SEMAX studies addressing BDNF, NGF, transcriptomics, neurotrophin receptors, inflammatory markers and experimental cerebral-ischemia models.

Adamax-specific evidence is considerably less straightforward in accessible peer-reviewed literature.

Therefore, a research article should not give both compounds equal evidentiary weight merely because they are presented beside one another commercially.

Direct evidence for the exact compound should always outrank analogy.

How strong is PE 22-28 evidence?

PE 22-28 has identifiable peer-reviewed preclinical work connected to the spadin/TREK-1 research line.

A published study describes PE 22-28 as a shortened peptide designed from spadin degradation products and reports electrophysiological testing against TREK-1, followed by animal-model investigation.

This provides a useful mechanistic starting point.

It still does not convert PE 22-28 into an established clinical treatment or justify consumer-use claims.

Why is evidence hierarchy so important in peptide content?

Peptide marketing often compresses very different kinds of evidence into one sentence.

A cell-culture observation, a rodent behavioral experiment, a small human study, a regulatory approval and a supplier COA are not interchangeable pieces of evidence.

They answer different questions.

A COA may say something about the tested material.

An animal study may say something about a biological hypothesis in that model.

A human clinical trial may answer a much narrower clinical question under controlled conditions.

A regulatory authorization determines a legal medical status in a particular jurisdiction.

Responsible research content preserves these boundaries rather than blending them together.

A practical SEMAX and SELANK procurement framework

For a laboratory comparing these products, a sensible sequence is:

First, define whether the hypothesis actually requires SEMAX, SELANK, or both.

Second, review direct published evidence for the exact compound and endpoint.

Third, identify the exact CertaPeptides product and current lot.

Fourth, determine whether that lot has independent third-party analysis or a supplier specification.

Fifth, read the analytical scope. Look separately at purity, measured content, identity-related information and anything else actually tested.

Sixth, preserve the batch documentation with the study records.

Seventh, review current shipping, returns, payment and institutional procurement requirements.

Only then should promotional pricing be considered.

That ordering helps prevent a commercial discount from driving a scientific decision.

Frequently asked questions

Are SEMAX and SELANK the same peptide?

No. SEMAX is an ACTH-fragment-derived synthetic peptide, while SELANK is a tuftsin-derived synthetic peptide. Their sequences and research backgrounds differ.

Does CertaPeptides list both compounds?

Yes. Current CertaPeptides pages list SEMAX and SELANK individually, and a combined SEMAX + SELANK research blend is also available.

Is the blend simply 20 mg of one peptide?

No. The published tested blend record reports component-specific content for both SEMAX and SELANK.

Does SEMAX have peer-reviewed research?

Yes. Multiple PubMed-indexed preclinical studies investigate SEMAX in areas including BDNF/NGF expression, neurotrophin signaling and cerebral-ischemia models.

Does that mean SEMAX is proven for personal cognitive enhancement?

No. Preclinical and mechanism-oriented research should not be converted into personal-use claims.

Does SELANK have published research?

Yes. Published literature has examined SELANK in neuropeptide and GABA-related experimental contexts.

What is PE 22-28?

PE 22-28 is a short peptide associated with the spadin/TREK-1 research line. Peer-reviewed work has investigated its TREK-1 activity and preclinical behavioral endpoints.

Is Adamax as well documented as SEMAX?

The accessible compound-specific literature is substantially thinner and less standardized, so researchers should be more cautious about claims derived from analogy or vendor descriptions.

What is the best COA number to look for?

There is no universally “best” number. Determine what was measured. Purity, identity and content answer different analytical questions.

Does 99.8% purity mean the vial contains exactly the labeled amount?

No. Purity and quantity are different measurements.

Are all CertaPeptides lots independently Janoshik tested?

The company's current transparency material says selected lots receive independent testing while other product lines are supported by supplier batch specifications.

How can a batch be checked?

Use the batch or report identifier in CertaPeptides' public verification system and, where applicable, compare the associated independent report with the issuing laboratory's record.

Where does CertaPeptides ship?

The current shipping page lists all 27 EU member states plus Switzerland, the United Kingdom, Iceland, and Serbia.

Are these products for human use?

No. CertaPeptides' current materials state that its research compounds are for laboratory/in-vitro research and are not intended for human or veterinary use.

What is the CertaPeptides promo code?

The campaign code is LOOT30.

What is the LOOT30 offer?

The campaign wording is up to 30% off.

Should a discount determine which peptide a researcher chooses?

No. Compound selection should follow the study question, literature and documentation. Price comes afterward.

Final perspective

SEMAX and SELANK are often placed side by side because both are short synthetic peptides associated with neurobiology research, but that similarity should not obscure their differences.

SEMAX belongs to an ACTH-fragment-derived research tradition with a substantial preclinical literature involving neurotrophic signaling, transcriptomic regulation and experimental ischemia models.

SELANK belongs to a tuftsin-derived research line that has been investigated in neuropeptide, immunological and GABA-associated experimental systems.

PE 22-28 adds a separate TREK-1/spadin-derived research pathway. Adamax requires more cautious interpretation because its direct compound-specific evidence is less clearly established. Cerebrolysin, VIP, DSIP and Dermorphin expand the catalog further but each presents a separate molecular and analytical problem.

For procurement, the most useful CertaPeptides feature is not simply that a COA page exists. It is the possibility of matching a physical batch to the appropriate documentation and distinguishing supplier specifications from independent third-party measurements.

Researchers should use that information precisely. A report from one lot should remain evidence about that lot. A purity percentage should remain a purity measurement. Preclinical biological findings should remain preclinical findings.

That evidence-first approach produces more defensible research than choosing materials from promotional language alone.

Qualified researchers who determine that the relevant CertaPeptides material, batch documentation, research restrictions and shipping arrangements meet their laboratory requirements can use the CertaPeptides LOOT30 research catalog with promo code LOOT30 for up to 30% off.

Strict research-use reminder: CertaPeptides materials discussed here are for controlled laboratory/in-vitro research only and are not for human or veterinary consumption, administration, diagnosis, treatment, cure, prevention, clinical application or personal experimentation.